Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.

OBJECTIVES the purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse pathophysiological pathways. BACKGROUND heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals are limited. METHODS in 5,187 individuals from the community-based MDCS (Malmö Diet and Cancer Study), we studied the performance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C, C-reactive protein (CRP), and copeptin. RESULTS during a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p < 0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p < 0.001), and MR-proANP (HR: 1.26 per SD, 95% CI: 1.02 to 1.56, p = 0.03) predicted incident heart failure independently of conventional risk factors and other biomarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p < 0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34, p = 0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors improved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the integrated discrimination improvement for both diseases (p < 0.001). Net reclassification improvement (NRI) with biomarkers was observed in 22% of individuals for heart failure (NRI, p < 0.001) and in 7% for atrial fibrillation (NRI, p = 0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%, atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification. CONCLUSIONS conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accuracy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrimination modestly for both diseases above and beyond conventional risk factors and substantially improve risk classification for heart failure.

[1]  P. Wilson,et al.  Incident Heart Failure Prediction in the ElderlyCLINICAL PERSPECTIVE , 2008 .

[2]  E. Ingelsson,et al.  The validity of a diagnosis of heart failure in a hospital discharge register , 2005, European journal of heart failure.

[3]  S. Yusuf,et al.  Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study , 2003, The Lancet.

[4]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[5]  Dirk Westermann,et al.  The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. , 2005, European heart journal.

[6]  Thomas J. Wang,et al.  Prediction of Heart Failure and Atrial Fibrillation ssessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers or the Prediction of Incident Heart Failure and Atrial Fibrillation , 2022 .

[7]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[8]  D. Levy,et al.  Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.

[9]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[10]  Tamara B Harris,et al.  Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score , 2008, Circulation. Heart failure.

[11]  P. Wilson,et al.  34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? , 2003, Journal of the American College of Cardiology.

[12]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[13]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[14]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[15]  D. Levy,et al.  Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop , 2009, Circulation.

[16]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[17]  D. Levy,et al.  Profile for estimating risk of heart failure. , 1999, Archives of internal medicine.

[18]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.

[19]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[20]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[21]  R. Rodeheffer,et al.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.

[22]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[23]  O. Melander,et al.  Atrial fibrillation in the Malmö diet and cancer study: a study of occurrence, risk factors and diagnostic validity , 2010, European Journal of Epidemiology.

[24]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[25]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[26]  M Rosén,et al.  A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. , 2001, International journal of epidemiology.

[27]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[28]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[29]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[30]  Ørnulf Borgan,et al.  A method for checking regression models in survival analysis based on the risk score , 1996, Lifetime data analysis.

[31]  D. Levy,et al.  Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study , 2009, The Lancet.

[32]  N. Beauchamp,et al.  Task Force #4 —How Do We Select Patients for Atherosclerosis Imaging? , 2003 .

[33]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[34]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[35]  R. Vasan,et al.  Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. , 2009, Archives of internal medicine.

[36]  Daniel Levy,et al.  The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.

[37]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[38]  P. Shekelle,et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.

[39]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.